Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1. (**Currently amended**) A method for treating cancer comprising administering chlorotoxin or a chlorotoxin derivative as a first agent and at least one chemotherapeutic agent as a second agent, wherein the two agents are administered simultaneously or are administered independently in a fashion that the agents will act at the same time,

   wherein the chlorotoxin derivative comprises a sequence selected from the group consisting of SEQ ID No. 1, SEQ ID No.2, SEQ ID No.3, SEQ ID No.4, SEQ ID No.5, SEQ ID No.6, SEQ ID No.7, SEQ ID No.8, SEQ ID No. 13, ~~portions thereof, and combinations thereof~~, and

   wherein the cancer is a member of the group consisting of human glioblastomamultiforme, human malignant melanoma, human prostate tumor, and human small cell lung carcinoma.

2. (**Original**) A method according to claim 1 wherein the chlorotoxin or chlorotoxin derivative is administered prior to administration of the chemotherapeutic agent.

3. (**Original**) A method according to claim 1 wherein the chlorotoxin or chlorotoxin derivative is administered subsequent to administration of the chemotherapeutic agent.

4. (**Original**) A method according to claim 1 wherein chlorotoxin or chlorotoxin derivative is administered simultaneously with the chemotherapeutic agent.

5. (**Original**) A method according to claim 1, wherein the chemotherapeutic agent is selected from the group consisting of alkylating agents, purine antagonists, pyrimidine

antagonists, plant alkaloids, intercalating antibiotics, aromatase inhibitors, anti-metabolites, mitotic inhibitors, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, anti-hormones and anti-androgens.

6. (**Previously presented**) A method according to claim 1, wherein the chemotherapeutic agent is selected from the group consisting of BCNU, cisplatin, gemcitabine, hydroxyurea, paclitaxel, temozolomide,topotecan, fluorouracil, vincristine, vinblastine, procarbazine, dacarbazine, altretamine, methotrexate, mercaptopurine, thioguanine, fludarabine phosphate, cladribine, pentostatin, cytarabine, azacitidine, etoposide, teniposide, irinotecan, docetaxel, doxorubicin, daunorubicin, dactinomycin, idarubicin, plicamycin, mitomycin, bleomycin, tamoxifen, flutamide, leuprolide, goserelin, aminoglutethimide, anastrozole, amsacrine, asparaginase, mitoxantrone, mitotane and amifostine.

7.-8. (**Canceled**)

9. (**Currently amended**) A composition for treating cancer comprising chlorotoxin or a chlorotoxin derivative and at least one chemotherapeutic agent,

wherein the chlorotoxin derivative comprises a sequence selected from the group consisting of SEQ ID No. 1, SEQ ID No.2, SEQ ID No.3, SEQ ID No.4, SEQ ID No.5, SEQ ID No.6, SEQ ID No.7, SEQ ID No.8, SEQ ID No.13, ~~portions thereof, and combinations thereof~~.

10. (**Original**) A composition according to claim 9, wherein the chemotherapeutic agent is selected from the group consisting of alkylating agents, purine antagonists, pyrimidine antagonists, plant alkaloids, intercalating antibiotics, aromatase inhibitors, anti-metabolites, mitotic inhibitors, growth factor inhibitors, cell cycle inhibitors, enzymes,

topoisomerase inhibitors, biological response modifiers, anti-hormones and anti-androgens.

11. (**Previously presented**) A composition according to claim 9, wherein the chemotherapeutic agent is selected from the group consisting of BCNU, cisplatin, gemcitabine, hydroxyurea, paclitaxel, temozolomide,topotecan, fluorouracil, vincristine, vinblastine, procarbazine, dacarbazine, altretamine, methotrexate, mercaptopurine, thioguanine, fludarabine phosphate, cladribine, pentostatin, cytarabine, azacitidine, etoposide, teniposide, irinotecan, docetaxel, doxorubicin, daunorubicin, dactinomycin, idarubicin, plicamycin, mitomycin, bleomycin, tamoxifen, flutamide, leuprolide, goserelin, aminoglutethimide, anastrozole, amsacrine, asparaginase, mitoxantrone, mitotane and amifostine.

12. (**Previously presented**) A composition according to claim 9, wherein the cancer is a member of the group consisting of human glioblastomamultiforme, human malignant melanoma, human prostate tumor, and human small cell lung carcinoma.

13-17. (**Canceled**)

18. **(Previously presented)** A method according to claim 1, wherein the chlorotoxin or chlorotoxin derivative is conjugated to at least one chemotherapeutic agent.

19. **(Previously presented)** A method according to claim 1, wherein the chlorotoxin or chlorotoxin derivative is conjugated to at least one chemotherapeutic agent and a pharmaceutically acceptable excipient.

20. **(Previously presented)** A method according to claim 18, wherein the chlorotoxin or chlorotoxin derivative is conjugated to a single species of chemotherapeutic agent.

21. **(Previously presented)** A method according to claim 18, wherein the chlorotoxin or chlorotoxin derivative is conjugated to multiple species of chemotherapeutic agents.